Open to privately owned Life Science companies and their Tech Transfer Office
|Achilles Therapeutics, UCL, CRT and the Francis Crick Institute|
|Apollo Therapeutics, Imperial Innovations, UCLB and Cambridge Enterprise|
|Cardian, Imperial Innovations|
|Circadian Therapeutics, Oxford University Innovation|
|GammaDelta Therapeutics, KCL / Francis Crick Institute and CRT|
|Keapstone Therapeutics, University of Sheffield|
|Microbiotica, Wellcome Trust Sanger Institute|
Open to privately owned Life Science companies that are between 1 and 3 years on from incorporation.
Open to privately owned Life Science companies that are greater than 3 years on from incorporation.
Open to either private or public life science companies, their Pharma partners and their Advisors.
|Abzena and undisclosed San Diego-based Biopharma - $300m licensing deal|
|Bicycle Therapeutics and AstraZeneca - $1bn peptide collaboration|
|Crescendo Biologics - Takeda $790m cancer collaboration|
|F-Star and Merck – €1bn immuno-oncology collaboration|
|GammaDelta Therapeutics and Takeda - $100m investment / acquisition option|
|PsiOxus Therapeutics and BMS - $936m deal|
|Summit Therapeutics and Sarepta - $584m+ DMD pipeline EU license pact|
|Vectura and Skyepharma merger|
Open to privately owned Life Science companies and their lead investors.
|Artios Pharma - £25m, Series A, SVLS, Touchstone Innovations, Arix Bioscience, Merck Ventures, Abbvie, CRT Pioneer Fund|
|Achilles Therapeutics - £13.2m, Seed Financing, Syncona, CRT Pioneer Fund and the UCL Technology Fund|
|ApcinteX - £14m Series A, Medicxi, Touchstone Innovations|
|Congenica - £10m, Series B, CIC, Amadeus Capital Partners, Parkwalk Advisors|
|NeRRe Therapeutics - £23m, Series B - Advent Life Sciences, Fountain Healthcare Partners, Orbimed, Forbion|
|Oxular - £15.5m, Series A, V-Bio Ventures,Touchstone Innovations, Consort Medical, NeoMed and Hovione Scientia|
|Pulmocide - £24m, Series B, SR-One, SV Life Sciences, Touchstone Innovations, JJVC, F-Prime Capital|
Open to privately owned Life Science companies and their lead investors.Atlas Genetics - £28.3m, Series D, Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation - JJDC, Inc., LSP, BB Biotech Ventures, RMI Partners and Technology Venture Partners, YFM Equity Partners and Wondfo Biotech
Open to newly publicly listed Life Science companies and their Advisors.
|ConvaTec - £1,465m raise, issue price £2.25p (CTEC:LSE)|
|CREO Medical - £21.5m raise, issue price £0.76p (CREO:LSE)|
|Medica Group - £15m raise, issue price £1.35p (MGP:LSE)|
|Oxford Biodynamics - £20m raise, issue price £1.58p (OBD:LSE)|
|SkinBio Therapeutics - £4.5m raise, issue price £0.09p (SBTX:LSE)|
|Verona Pharma - $78m raise, issue price $13.50 (VRNA:US NASDAQ)|
|Widecells - £2m raise, issue price £0.113p (WDC:LSE)|
Open to publicly listed Life Science companies and their Advisors. Raise must be non-IPO.
|Abzena - £25m raised to expand further its service offering, capacity and capabilities|
|C4X Discovery - £7m raised to continue to build its existing pipeline of five preclinical assets|
|Genedrive - £6.5m raised to broaden the portfolio of its Genedrive tests, developed to fight infectious diseases|
|Midatech Pharma - £16m raised to expand and advance its oncology-focused development pipeline|
|Oxford BioMedica - £10m raised to fund progress on its discovery and pre-clinical projects|
|Scancell Holdings - £5m raised to fund clinical work on its pipeline of cancer immune-therapies|
|Verona Pharma - £44.7m raised to fund RPL554 through a phase 2b clinical trial in chronic obstructive pulmonary disease (COPD) patients and additional phase 2 studies in both COPD and cystic fibrosis|
Open to pubicly owned Life Science companies only.
Open to private or public life science companies and their PR / IR and Strategic Communications Firm.
|Astex Pharmaceuticals and Instinctif|
|Evgen Pharma and Buchanan|
|F2G and Hume Brophy|
|Heptares Therapeutics and Citigate Dewe Rogerson|
|Horizon Discovery and Consilium Strategic Communications|
|Optibiotix and Walbrook PR|
|Verona Pharma and FTI Consulting|
Open to CEOs from both privately and publicly owned Life Science companies.
|Anker Lundemose, MISSION Therapeutics|
|Christian Itin, Autolus|
|David Chiswell, Kymab|
|Gordon Sanghera, Oxford Nanopore|
|John Beadle, PsiOxus Therapeutics|
|John Haurum, F-Star|
|Kevin Lee, Bicycle Therapeutics|
|Peter Pack, Crescendo Biologics|
|Clive Dix, C4X Discovery|
|Dame Louise Makin, BTG|
|Darrin Disley, Horizon Discovery|
|Glyn Edwards, Summit PLC|
|James Ward-Lilley, Vectura|
|John Burt, Abzena|
|John Dawson, Oxford BioMedica|
|Shaun Chilton, Clinigen|